Sanofi US News

- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy -

The Coalition to Prevent DVT Sends Awareness into Motion with an Educational Program Focusing on Preventative Care Through Movement

New Data Published by Journal of American Academy of Dermatology Demonstrated Sustained Efficacy Up to 25 Months

"AFib Support Team" Offers Insights on Comprehensive Approach to Management of Serious Heart Condition

Fluzone® High-Dose (Influenza Virus Vaccine) strengthens immune response in the 65+ population, an age group that suffers disproportionately from influenza and its complications

-- Combination Strengthens sanofi-aventis' Strategy to Accelerate Growth Through Innovation, Geographic Expansion and External Growth

Novel vaccine approach tested against one of the most common causes of hospital-acquired infection in Europe and North America

- Atul Dhir, M.D., Ph.D. has been appointed new BiPar CEO to continue growing entrepreneurial and innovative culture -

Final data confirm immunogenicity, safety profile

The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated

- Elitek is now approved to manage a potentially life-threatening complication associated with anti-cancer treatment in adults -

The first clinical trial data from America’s youngest vaccine recipients, children 6 months through 9 years of age, show the vaccine induces an immune response and is well-tolerated

Taking Control of Your Diabetes (TCOYD) Calls on Marketing Leaders and Creative Minds to "Start Taking Action Now for Diabetes"

Data from studies in adults 18 years of age and older provide confirmation that one dose of vaccine produces a robust immune response even in those over the age of 65 years

Women may delay treatment or seek injectable procedures

Company has now committed to produce 75.3 million doses of vaccine for the U.S. government